相关实验视频

Updated: Jul 16, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

抗PD-1治疗对复发或耐药的古典霍奇金淋巴瘤患者的长期生存益处

Weiping Liu¹, Ningjing Lin¹, Xinqin Feng²

¹Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Signal transduction and targeted therapy

|September 19, 2023

概括

反编程细胞死亡-1 (抗PD-1) 疗法有利于复发或耐药的古典霍奇金淋巴瘤 (cHL) 患者. 然而,部分缓解和耐药性疾病会对长期生存产生负面影响,这表明需要采用多模式策略.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
血液学血液学血液学

背景情况:

抗编程细胞死亡-1 (抗PD-1) 疗法在复发性或耐火性 (r/r) 经典霍奇金淋巴瘤 (cHL) 中显示出有效性.
对于r/rcHL患者实现对抗PD-1治疗的客观反应的长期结果,数据有限.

研究的目的:

评估对抗PD-1治疗有反应的r/rcHL患者的长期结果.
在这个患者队列中确定影响无进展生存 (PFS) 和整体生存 (OS) 的因素.

主要方法:

在r/rcHL中对抗PD-1治疗的四个临床试验的260名响应者的分析.
平均随访时间为31.1个月,评估疾病进展和生存率.
多变量考克斯回归分析以确定PFS的独立风险因素.

主要成果:

三年PFS和OS率分别为55.1%和89.7%.
实现完全缓解 (CR) 的患者比部分缓解 (PR) 的患者有明显更好的结果 (3年PFS: 72.3%与29.5%相比; 3年OS: 94.4%与81.5%相比).
与复发性疾病相比,耐药性疾病与较差的生存结果有关.

结论:

部分缓解和耐药性疾病是与抗PD-1疗法治疗的r/rcHL患者中PFS的独立负面预测因素.
这些发现强调了对PR或耐火性疾病患者的强化或多模式治疗策略的需要.
抗PD-1疗法提供持久的反应,但仔细的患者选择和治疗规划对于优化长期生存至关重要.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...